1.Associations of smoking with overall obesity, and central obesity: a cross-sectional study from the Korea National Health and Nutrition Examination Survey (2010-2013).
Yeonjung KIM ; Seong Min JEONG ; Bora YOO ; Bitna OH ; Hee Cheol KANG
Epidemiology and Health 2016;38(1):e2016020-
OBJECTIVES: The association between smoking and obesity is a significant public health concern. Both are preventable risk factors of cardiovascular disease and a range of other conditions. However, despite numerous previous studies, no consensus has emerged regarding the effect of smoking on obesity. We therefore carried out a novel study evaluating the relationship between smoking and obesity. METHODS: A total of 5,254 subjects aged 19 years or older drawn from the 2010-2013 Korea National Health and Nutrition Examination Survey were included in this cross-sectional study. Smoking was examined both in terms of smoking status and the quantity of cigarettes smoked by current smokers. Multiple logistic regression analysis was used to assess the association between smoking and obesity. Overall obesity was defined as a body mass index (BMI) ≥25 kg/m2, and central obesity was defined as a waist circumference ≥90 cm for males and ≥85 cm for females. We adjusted for the possible confounding effects of age, sex, physical activity, alcohol consumption, and the presence of hypertension or diabetes. RESULTS: A statistically significant difference in central obesity according to smoking status was identified. Current smokers were more likely to be centrally obese than never-smokers (adjusted odds ratio,1.30; 95% confidence interval, 1.02 to 1.67). However, no significant association was found between smoking and obesity defined by BMI. Moreover, among current smokers, no statistically significant association was found between the daily amount of smoking and obesity or central obesity. CONCLUSIONS: Smoking was positively associated with central obesity. Current smokers should be acquainted that they may be more prone to central obesity.
Alcohol Drinking
;
Body Mass Index
;
Cardiovascular Diseases
;
Consensus
;
Cross-Sectional Studies*
;
Female
;
Humans
;
Hypertension
;
Korea*
;
Logistic Models
;
Male
;
Motor Activity
;
Nutrition Surveys*
;
Obesity*
;
Obesity, Abdominal*
;
Public Health
;
Risk Factors
;
Smoke*
;
Smoking*
;
Tobacco Products
;
Waist Circumference
2.Aerosol delivery of kinase-deficient Akt1 attenuates Clara cell injury induced by naphthalene in the lungs of dual luciferase mice.
Arash MINAI-TEHRANI ; Young Chan PARK ; Soon Kyung HWANG ; Jung Taek KWON ; Seung Hee CHANG ; Sung Jin PARK ; Kyeong Nam YU ; Ji Eun KIM ; Ji Young SHIN ; Ji Hye KIM ; Bitna KANG ; Seong Ho HONG ; Myung Haing CHO
Journal of Veterinary Science 2011;12(4):309-317
Conventional lung cancer therapies are associated with poor survival rates; therefore, new approaches such as gene therapy are required for treating cancer. Gene therapies for treating lung cancer patients can involve several approaches. Among these, aerosol gene delivery is a potentially more effective approach. In this study, Akt1 kinase-deficient (KD) and wild-type (WT) Akt1 were delivered to the lungs of CMV-LucR-cMyc-IRES-LucF dual reporter mice through a nose only inhalation system using glucosylated polyethylenimine and naphthalene was administrated to the mice via intraperitoneal injection. Aerosol delivery of Akt1 WT and naphthalene treatment increased protein levels of downstream substrates of Akt signaling pathway while aerosol delivery of Akt1 KD did not. Our results showed that naphthalene affected extracellular signal-regulated kinase (ERK) protein levels, ERK-related signaling, and induced Clara cell injury. However, Clara cell injury induced by naphthalene was considerably attenuated in mice exposed to Akt1 KD. Furthermore, a dual luciferase activity assay showed that aerosol delivery of Akt1 WT and naphthalene treatment enhanced cap-dependent protein translation, while reduced cap-dependent protein translation was observed after delivering Akt1 KD. These studies demonstrated that our aerosol delivery is compatible for in vivo gene delivery.
Administration, Inhalation
;
Aerosols
;
Animals
;
Gene Expression Regulation
;
Gene Knockdown Techniques
;
Gene Therapy/*methods
;
Gene Transfer Techniques
;
Genes, Reporter
;
Injections, Intraperitoneal
;
Luciferases/genetics/*metabolism
;
Lung Diseases/*chemically induced
;
Male
;
Mice
;
Mice, Transgenic
;
Naphthalenes/administration & dosage/*toxicity
;
Proto-Oncogene Proteins c-akt/*administration & dosage/genetics/*metabolism